Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALB | P02768 | 2/20 | 0.55 |
| ▸ | BLM | P54132 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | TK1 | P04183 | 6/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7701755 | 1.00 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL1129570 | 1.00 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL1130181 | 1.00 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL6760136 | 1.00 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL1129572 | 1.00 | LMNA (0.55) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL14580339 | 0.87 | TK1 (0.48) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL2920441 | 0.86 | TK1 (0.52) | LMNATK1 | |
| SCHEMBL2920443 | 0.86 | TK1 (0.52) | LMNATK1 | |
| SCHEMBL6753208 | 0.84 | SMN1; SMN2 (0.54) | LMNABLMALDH1A1POLBADRA1A | |
| SCHEMBL6752642 | 0.84 | LMNA (0.60) | LMNAADRA1ATK1TSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903224-B2 | Substituted 1,3-oxathiolanes | BIOCHEM PHARMA INC. (CA) | 2005-06-07 | — | — | US | disclosed |
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | BIOCHEM PHARMA INC. (CA) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087918-A1 | Synthesis of substituted 1,3-dioxolanes and substituted 1,3-oxathiolanes with antiviral properties | IFNAR1, ZC3HAV1, NUDT1 | LMNA 3528/4885ALB 2629/4885BLM 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.